Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

  title={Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol},
  author={Kausik K. Ray and Ulf Landmesser and Lawrence A Leiter and David G. Kallend and Robert Dufour and Mahir Karakas and Tim Hall and Roland P.T. Troquay and Traci A Turner and Frank L. J. Visseren and Peter L. J. Wijngaard and R. Scott Wright and John J Kastelein},
  journal={The New England Journal of Medicine},
BACKGROUND In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low‐density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers. METHODS We conducted a phase 2, multicenter, double‐blind, placebo‐controlled, multiple‐ascending‐dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for… 

Figures from this paper

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Reductions in low-density lipoprotein cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months in patients with atherosclerotic cardiovascular disease and patients who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose.

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.

Those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile; there were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia.

Inclisiran: How Widely and When Should We Use It?

It is shown that inclisiran provides robust and durable reductions of PCSK9 and LDL-C levels, with a dosing schedule of once every 6 months after the initial and 3-month doses, and the administration schedule may improve patients’ compliance given the favourable safety profile of the drug.

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.

Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year and may offer a novel approach to cholesterol reduction with the convenience of infrequent dosing, as well as noting similar effects observed for PCSK9.

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis

Inclisiran is a disruptive, first-in-class small interfering RNA (siRNA)-based therapeutic developed for the treatment of hypercholesterolemia that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) synthesis, thereby upregulating the number of LDL receptors on the hepatocytes, thus lowering the plasma LDL-C concentration.

An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease

The infrequent dosing regimen offers a major advantage to improve long term compliance and inclisiran may be extensively adopted depending on the cost.

Evolocumab and clinical outcomes in patients with cardiovascular disease.

Patients of atherosclerotic cardiovascular disease will benefit from lowering of LDL cholesterol levels till 30 mg/dl, well below current treatment targets, according to FOURIER study.



Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis.

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

In healthy, normolipidemic subjects, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerating their catabolism.

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

It is indicated that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial Reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

Results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition, and suggest that increased LDL receptors may also play a role in the reduction of plasma Lp(a) levels.

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.

Data support guideline approaches that incorporate % reduction targets for statin therapy as well as absolute targets, and might provide a structure for the allocation of emerging adjunctive lipid-lowering therapies such as PCSK9 inhibitors should these agents prove broadly effective for cardiovascular event reduction.